The relationship between lopinavir plasma concentration and the magnitude of lipid elevation after initiation of lopinavir/ritonavir-containing antiretroviral therapy is unclear. The aim of this study was to determine the relationship between drug concentration and lipid changes in two patient cohorts. Methods: First, we analysed, in an outpatient cohort, the correlation between percentage lipid changes and lopinavir concentration, measured at least 2 weeks or more after initiation of lopinavir/ritonavir. Second, we analysed the correlation between lipid changes and lopinavir and ritonavir plasma concentrations in antiretroviral-naive patients enrolled in a trial comparing nevirapine plus lopinavir/ritonavir (533/133 mg twice daily) with zidovudine/lamivudine plus lopinavir/ ritonavir (400/100 mg twice daily). The HIV protease inhibitor (PI) lopinavir (LPV) is administered twice a day combined with a low dose of the PI ritonavir (RTV), which increases the systemic availability of LPV by inhibiting cytochrome P450 3A4 (so-called 'boosting'). RTV-boosted LPV (LPV/r) has been proven to be an effective antiretroviral drug in many trials [1, 2] , and has had a profound effect on the survival of HIV-infected patients [3] . However, boosted PI-containing combination antiretroviral therapy (cART) is associated with adverse events such as dyslipidaemia, insulin resistance, fat redistribution, hypertension and diabetes mellitus [4] . Furthermore, PI use increases the risk of developing cardiovascular diseases, LPV/r in particular [5] [6] [7] . In a large cohort studying adverse events of cART (the D:A:D study), the relative risk of myocardial infarction increased 16% for every year of PI exposure [5] . Adjusting for other factors, it was observed that the effect of PIs on the risk for myocardial infarction was partly explained by dyslipidaemia. An increase in plasma lipids has often
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been described in patients using PIs [8] . For example, in a recent trial comparing RTV-boosted fosamprenavir with LPV/r-based cART in antiretroviral-naive patients, total cholesterol increased 39% and 33%, respectively, and triglycerides increased 60% and 66%, respectively, after 48 weeks [9] .
Low LPV plasma concentrations are associated with virological failure, especially in treatment-experienced patients [10] . Therefore, in the follow-up of patients treated with LPV/r, therapeutic drug monitoring (TDM) has been recommended to determine whether an adequate plasma concentration has been reached to assure optimal viral suppression [11] . In contrast to its association with virological failure, current literature is not in agreement on whether there is a relation between the plasma concentration of LPV and the extent of lipid increase after starting LPV/r-containing cART [12] [13] [14] [15] [16] [17] . Importantly, most previous studies included a small number of patients patients) from a heavily pre-treated population and had a short follow-up. Besides LPV, RTV is found to elevate lipid levels as well, even with the boosting dose of 100 mg twice a day [18, 19] . In healthy patients, a correlation between change in lipids and RTV plasma concentration, as well as RTV dosage, has been shown [20] . However, of the previously mentioned studies involving HIVinfected patients, only one also determined RTV concentrations. Indeed, a positive relation between RTV plasma concentrations and total cholesterol increases was found [14] .
Because of these inconclusive results, we analysed patients from our HIV outpatient clinic in search of a relation between LPV plasma concentrations and elevation of lipids. Additionally, we measured RTV as well as LPV plasma concentrations in a cohort of antiretroviral-naive patients enrolled in a trial that compared a nucleoside reverse transcriptase inhibitor (NRTI)-sparing regimen (nevirapine [NVP] plus LPV/r) with zidovudine/lamivudine (ZDV/3TC) plus LPV/r [21] .
Methods

Outpatients
First, HIV-1-infected patients in routine care at our HIV treatment centre in the period following introduction of LPV/r (2001-2007) were studied. All patients treated with LPV/r-containing cART were included whose LPV plasma concentrations were measured at least once, 2 weeks or more after initiation of LPV/r to ensure a steady-state concentration. Patients using lipid-lowering drugs at the time of the measurement were excluded to avoid confounding. Data from patient records and data collected for the AIDS Therapy Evaluation in The Netherlands (ATHENA) cohort study, a nationwide observational cohort study of HIV-infected patients in the Netherlands, were utilized. All patients provided written informed consent. Importantly, information on patient adherence has been incompletely recorded in this database. As a proxy for adherence we used HIV RNA at the time of the LPV plasma concentration measurement. HIV RNA>50 copies/ml was considered an indication of possible non-adherence if measured more than 6 months after initiation of LPV/rcontaining cART.
Trial patients
Second, HIV-1-infected patients were studied who were enrolled in the multicentre, randomized Metabolic Effects of Different Classes of Antiretrovirals (MEDI-CLAS) trial, which has been described in detail [21] . In brief, the trial compared ZDV/3TC 300/150 mg twice daily plus LPV/r 400/100 mg capsules twice daily with the NRTI-sparing regimen of NVP 200 mg twice daily (following a 2-week 200 mg once daily lead-in) plus LPV/r 533/133 mg twice daily in 50 antiretroviral-naive HIV-1-infected men to compare the metabolic complications of both treatment strategies. The higher dose of LPV in the latter arm of the trial was given in order to achieve comparable LPV plasma concentrations in both trial arms, since LPV exposure can be expected to decrease through NVP-associated CYP3A4 induction [22] . Exclusion criteria were extreme obesity, diabetes mellitus, a history of hyperlipidaemia, or use of lipid-lowering drugs, nandrolone or testosterone. The study was approved by the ethics committees of all participating centres, and each patient provided written informed consent. As a post hoc analysis, LPV and RTV concentrations were measured in stored serum samples drawn at 12 and 24 months of follow-up.
Lipids and drug plasma concentrations
We determined lipid concentrations including total cholesterol, high-density lipoprotein cholesterol (HDLc) and triglycerides. Low-density lipoprotein cholesterol (LDLc) concentrations were calculated using the Friedewald formula, unless triglyceride concentrations were >4.52 mmol/l [23] . We calculated percentage changes in total cholesterol, HDLc, LDLc and triglyceride levels by dividing the lipid concentrations at the time of the LPV plasma concentration measurement by the corresponding concentrations at start of the LPV/r-based therapy. For outpatients, a maximum time gap of 3 months between lipid and LPV measurement was allowed. In these patients, whether the samples were drawn in a fasting state was not recorded.
We determined LPV and RTV concentrations by validated high-performance liquid chromatography using diode array detection. Samples of outpatients were measured in the clinical pharmaceutical and toxicological laboratory of The Hague Hospitals, The Hague, the Netherlands. The MEDICLAS trial samples were measured in the pharmacology laboratory of the Radboud University Nijmegen Medical Centre, Nijmegen, the Netherlands. Both laboratories participate in an external quality control programme. Because in both cohorts most samples were not trough samples, LPV and, where applicable, RTV concentration ratios were calculated by dividing the measured LPV and RTV plasma concentration by the expected concentration from population-based reference curves [24] at the corresponding sampling time after the last dosage. The same curve was used in trial patients using LPV/r plus ZDV/3TC and those patients using LPV/r plus NVP. Notably, the time of last dosage was recorded for all patients. Whether or not LPV/r was taken with food in accordance with instructions was not recorded.
Statistical analyses
To correct for a left-skewed distribution of the lipid changes we used logarithmic transformations in the analyses. We analysed the relationship between the percentage change in lipid levels and the LPV concentration ratio, and in trial patients also the RTV concentration ratio, with simple and multiple linear regression. For the analyses in the outpatient cohort we included all LPV measurements allowing a single individual contributing multiple measurements. Additionally, to correct for multiple measurements in individual patients we performed a repeated-measures analysis in a mixed model and we performed a sensitivity analysis using only the first measurement of each outpatient.
In outpatients we estimated any correlation between LPV concentration ratio and percentage lipid change from LPV/r initiation by Pearson's correlation analysis. Next, we used multivariable linear regression analyses to assess the influence of age, gender, prior cART regimens (no prior treatment, non-NRTI-based, PI-based, both non-NRTI-and PI-based, and only NRTI-based cART), other components of current cART (no non-NRTI, efavirenz [EFV] or NVP), CD4 + T-cell count at initiation of LPV/r and duration of LPV/r use. Because lipids tend to rise after initiation of cART due to improvement of the clinical condition of the patient, we also analysed a subgroup of patients that had been treated with cART prior to LPV/r initiation.
In trial patients we included LPV and RTV concentration ratios in the Pearson's correlation analysis to estimate any correlation between drug concentration and percentage lipid change. We used multivariable regression analyses with lipid percentage change at 24 months from baseline as the dependent variable and LPV and RTV concentration ratios and treatment (LPV/r plus ZDV/3TC or LPV/r plus NVP) as independent variables. In the analyses we included data (drug and lipid concentrations) of all patients that were still in follow-up at the time of sampling, whether the patient was still using LPV/r or not (intention-to-treat). Additionally, we performed repeated-measures analyses including data from 12 and 24 months of follow-up.
For our statistical analyses we used the SPSS statistical software package (version 16.0 for Macintosh; SPSS Inc., Chicago, IL, USA).
Results
Lopinavir plasma concentrations and lipid changes in outpatients
During the period 2001-2007, 327 patients were under treatment for HIV infection in our centre, of whom 177 patients (54%) were treated with LPV/r-based cART. We selected 89 patients treated with LPV/r, whose LPV plasma concentration was measured at least once (median 2 times, range 1-15) 14 days or more after the start of LPV/r. After exclusion of seven patients who were using lipid-lowering drugs at the time of the measurement, we included 215 LPV plasma concentration measurements from 82 patients in our analyses. At the time of LPV plasma measurement, detectable HIV RNA (>50 copies/ml) more than 6 months after initiation of LPV/r was observed in 64 out of 215 samples (30%). Patient characteristics are shown in Table 1 .
Including all samples (n=215), the median calculated LPV plasma concentration was 6.1 mg/l (IQR 3.7-8.6) and the median LPV concentration ratio was 0.74 (IQR 0.42-0.99). The mean percentage increases in lipids from initiation of LPV/r were 7.26% (95% CI 3.20-11.5) for total cholesterol, 16 Table 2 and Figure 1 ). Both in a repeated-measures analysis and in a sensitivity analysis using only the first measurement of each outpatient (n=82), no significant correlations were again found between LPV plasma concentration ratio and percentage increase in any of the lipids (WFWB, data not shown). When excluding the samples of patients with detectable HIV RNA (n=64) who had a significantly lower median LPV concentration ratio compared with the other patients (0.55 versus 0.79; P=0.001), no significant correlations between the calculated LPV plasma concentration ratio and percentage increase in lipids were found either (WFWB, data not shown).
Adjustment for age, sex, prior therapy, non-NRTI as a component of current cART, CD4 + T-cell count at the start of LPV/r and duration of LPV/r use in multivariable analyses did not result in a significant relation between the LPV concentration ratio and percentage change in lipids. Variables significantly associated with percentage lipid changes were: total cholesterol, prior PI use (standardized regression coefficient β=-0. 29 When limiting the analyses to a subgroup of patients who had received other antiretroviral therapy before starting LPV/r therapy (n=49), the correlation between the LPV concentration ratio and the change in HDLc was borderline significant (r=-0.225, P=0.054), but not significant between the LPV concentration ratio and the increase in total cholesterol, LDLc and triglycerides (r=0.119, P=0.105; r=0.088, P=0.279 and r=0.057, P=0.280, respectively). Adjusting for significant confounders (prior non-NRTI use, concurrent EFV use, duration of LPV/r use and sex), the correlation between the LPV concentration ratio and HDLc change became significant (β=-0.377, P=0.004).
Ritonavir and lopinavir plasma concentrations and lipid changes in trial patients
In the MEDICLAS trial, 50 patients were included; 23 were randomly assigned to ZDV/3TC/LPV/r and 27 Table 2 . LPV plasma concentrations and lipid concentrations of outpatients with TDM of LPV as part of routine practice Data presented as mean (95% CI), unless otherwise indicated. a Lopinavir (LPV) concentration ratios were calculated by dividing the measured concentration by the expected concentration from a population-based reference curve [24] . HDL, high-density lipoprotein; LDL, low-density lipoprotein; LPV/r, ritonavir-boosted lopinavir; TDM, therapeutic drug monitoring.
to NVP/LPV/r. Median (IQR) age was 40 (34-51), all were male and the median CD4 + T-cell count was 210 (142-340) cells/ml. Lipid changes, and LPV and RTV concentrations and ratios at 24 months are shown in Table 3 . At 24 months, the median LPV plasma concentration was lower in the ZDV/3TC/LPV/r group 
Discussion
In a cohort of 82 outpatients with 215 TDM LPV samples on mainly first-line or second-line LPV/r-containing cART in routine practice, we found no relation between the measured LPV plasma concentration (or LPV concentration ratio) and the change in lipid levels. Adjusting for the potential influence of age, sex, CD4 + T-cell count at the start of LPV/r, non-NRTI as a component of current cART and duration of LPV/r use did not change this. In addition, in 50 antiretroviral-naive patients included in a randomized controlled trial comparing LPV/r 400/100 mg plus ZDV/3TC twice daily and LPV/r 533/133 mg plus NVP twice daily, LPV and RTV plasma concentrations (and concentration ratios) were not related to lipid changes.
Previous studies on the relationship between LPV concentration and lipid changes are conflicting. Studies that did find a correlation between high LPV plasma concentrations and lipid increases have in common that the data were obtained at planned, protocol visits in prospective trials with either short follow-up (3 months) or a small number (19) (20) (21) (22) (23) (24) (25) (26) (27) (28) (29) (30) of patients [13, 14, 17, 25] . Furthermore, these trials were carried out in a heavily pre-treated population. Studies that did not find a correlation between LPV concentrations and lipid changes had similar epidemiological flaws [12, 15, 16, 26] . In comparison, our study was larger, had a longer follow-up and examined mainly patients on first-line or second-line therapy. Moreover, the analyses performed in the outpatient cohort had the advantage of examining a representative population of patients in routine care, while the analyses performed in the trial cohort had the advantage of scheduled monitoring in an optimal, controlled setting.
Why did we not find an association between PI concentration and lipid changes? The mechanism through which PIs cause elevated lipid levels is not well understood [27] . Research focuses on how PIs impair lipoprotein clearance and/or increase hepatic cholesterol and triglyceride synthesis. Additionally, an association between PI-induced lipid elevations and inhibition of the proteasome in the liver of a rat model has been recently described, conceivably through reduced degradation of proteins involved in the lipid homeostasis by the proteasome [28] . In spite of an unravelled mechanism, the lack of an association between drug concentration and effect on lipids suggest that pharmacokinetics do not play a role. However, a concentration-related effect of PIs on lipids at very low drug concentrations could still contribute. Furthermore, part of the observed lipid changes in cART in antiretroviral-naive patients is caused by the improvement of the patient's condition and should not be seen as the direct side effect of the drugs used [29] . Lipid changes after initiation of cART could be partly related to the reversal of immune activation and inflammation. In the multivariable analyses this was partly controlled for, since the duration of LPV/r did not appear to be a significant covariate. Interestingly, within a subgroup analysis of all outpatients that were not antiretroviral-naive before starting LPV/r, we did find a correlation between the LPV concentration ratio and percentage HDLc increase after adjusting for significant confounding factors (prior non-NRTI use, concurrent EFV use, duration of LPV/r use and sex). A higher LPV concentration ratio was associated with a lower percentage increase in HDLc. In this pre-treated subgroup, condition-related lipid changes, reflected by a higher CD4 + T-cell count (median 290 cells/ml) compared with the antiretroviral-naive subgroup (median 130 cells/ml), presumably do not play an important role. Therefore, the described correlation is more likely to reflect merely LPV/r-induced lipid changes.
To determine whether the plasma concentration of the boosting component of LPV/r contributed to the lipid changes after initiating LPV/r, we retrospectively measured RTV plasma concentrations in our trial patients. RTV plasma concentrations correlated well with LPV plasma concentrations (r=0.8; P<0.001) and therefore, similarly, did not correlate with lipid changes. By contrast, in a relatively large (126 patients in an expanded access programme) but short (3 months) trial, higher LPV concentrations were associated with increased triglyceride elevations, while RTV concentrations were positively correlated with total cholesterol elevations [14] . The authors did not adjust for possible confounding factors, such as the other cART components and the prior combinations used. Collot-Teixeira et al. [20] recently also found a relation between RTV plasma concentrations and lipid changes; that is, a decrease in HDLc and an increase in triglycerides with higher RTV concentrations. However, that study was conducted with RTV 100 mg once or twice daily without LPV in healthy volunteers and had a short follow-up.
In the Netherlands, LPV plasma concentrations are frequently measured within the framework of routine TDM [30] , because even under standardized circumstances a significant interpatient variability exists in the measured plasma concentrations of LPV when administered at a standard dose [31] . Other indications for measuring LPV plasma concentrations are suspected non-adherence, drug interactions and presumed virological failure on LPV/r-based cART. This mix of indications may have influenced the relationship between LPV concentrations and lipid changes in the outpatient cohort. Importantly, possible non-adherence was indicated in 30% of the outpatients based on detectable HIV RNA. However, when excluding these patients, who indeed had a significantly lower median LPV plasma concentration than the other patients (0.55 versus 0.79; P=0.001), LPV concentrations and lipid changes were still not correlated.
Notably, after exclusion of patients with detectable HIV RNA the median LPV plasma concentration was still low compared with the reference curve. Yet, the reference population curve was derived after observed intake of LPV/r capsules with food, while in the clinical setting patients may have taken the medication without food or the time between sampling and intake may be less accurate. Next, in routine practice it is not always possible to maintain the same standard of drug concentration measurement as during trials; for example, patients arrive at different times of the day to have their blood drawn, resulting in varying intervals between LPV/r intake and concentration measurement. To correct for this variation we used the LPV concentration ratio in our analyses. In addition, we repeated the analyses with only the absolute concentrations of LPV and this did not change our correlations, which is in line with the relatively small difference between peak and trough LPV concentrations (that is, twofold).
Another limitation of the analyses of our outpatient cohort was its heterogeneous data source, which could have introduced bias. On the other hand, the heterogeneity of the population enables extrapolation of our results to other routine care settings. An additional limitation was the varying number of measurements per patient. However, correcting this in two ways (a repeated-measures analysis and a sensitivity analysis including only the first measurement of each outpatient), no significant relation between lipid changes and PI concentration was found. Moreover, in trial patients, all analyses, including repeated-measures analyses, showed similar results. Finally, most lipid concentrations were probably not measured in fasting samples, which could have reduced the accuracy of triglyceride and LDLc results. Still, it is unlikely that this would have substantially influenced our analyses regarding the relation between LPV plasma concentrations and lipid changes.
Thus, as higher LPV (or RTV) plasma concentrations are not associated with increased lipid elevations, one can conclude that TDM is not useful in prediction and prevention of hyperlipidaemia. Other, probably genetic, features are more likely to determine which patients will develop hyperlipidaemia after initiating LPV/r regardless of pharmacokinetics. Associations between single nucleotide polymorphisms of several apolipoproteins and dyslipidaemia have been found in patients using PI-containing antiretroviral therapy [32] . Nevertheless, even more advanced multi-gene models are still not very accurate in predicting dyslipidaemia after initiating antiretroviral therapy [32] , implying a multifactorial causal relationship between PI use and dyslipidaemia. An increase in lipid levels in an individual patient may rather be an on/off phenomenon based on this multifactorial relationship. As a consequence, even if LPV concentrations are found to be in a higher range, in patients developing hyperlipidaemia, a change of treatment regimen may be warranted rather than reducing the LPV/RTV dosage.
